Summary

Persistence Market Research has recently released an extensive report on the global Inflammatory Bowel Disease (IBD) Market, providing a thorough analysis of key market dynamics. This detailed report explores the factors driving the market, emerging trends, opportunities, and challenges, offering valuable insights into the market structure and its future growth path.

Key Insights:

• Inflammatory Bowel Disease Market Size (2024E): US$22 Bn
• Projected Market Value (2031F): US$29.1 Bn
• Global Market Growth Rate (CAGR 2024 to 2031): 4.1%

Inflammatory Bowel Disease Market - Report Scope:

The report covers the Inflammatory Bowel Disease Market, which includes various treatments and medications designed to manage IBD, including Crohn's disease and ulcerative colitis. These treatments range from anti-inflammatory drugs and immunosuppressants to biologics and surgical interventions. The market caters to a broad patient base, from those with mild symptoms to severe cases, across multiple settings such as hospitals, specialty clinics, and home care environments. The growth of the IBD market is primarily fueled by the increasing prevalence of the disease, advancements in treatment options, and greater awareness and diagnosis of IBD across diverse demographic groups.

Market Growth Drivers:

Several key factors are propelling the growth of the global Inflammatory Bowel Disease Market. The rising prevalence of IBD worldwide is a significant driver, with heightened awareness and improved diagnostic tools leading to more cases being identified. Advances in treatment options, particularly the development of biologics and biosimilars, have greatly enhanced patient quality of life, thereby supporting market expansion. Furthermore, increased investment in research and development (R&D) for new therapies, along with the expansion of healthcare infrastructure in emerging markets, contributes to market growth. The focus on personalized medicine and the development of targeted therapies tailored to individual patient needs are also crucial in driving the market forward.

Market Restraints:

Despite the positive outlook, the Inflammatory Bowel Disease Market faces several challenges. The high cost of biologic therapies and the long-term nature of treatment for chronic conditions like IBD pose significant barriers, particularly in regions with limited healthcare funding or insurance coverage. Additionally, the side effects associated with some IBD treatments, such as immunosuppressants and corticosteroids, may discourage patients from adhering to prescribed therapies. The market also faces competition from alternative treatments, including dietary changes and holistic approaches, which some patients prefer due to concerns about the long-term use of pharmaceuticals. These challenges underscore the need for continued R&D to develop more effective and safer treatment options.

Market Opportunities:

The IBD market offers substantial growth opportunities, particularly in the development of novel therapies and the increasing adoption of biosimilars. The growing interest in personalized medicine provides opportunities for companies to create targeted therapies that address specific patient subgroups, potentially improving treatment outcomes and reducing side effects. Additionally, the expansion of telemedicine and digital health platforms presents new avenues for patient management and follow-up, enhancing access to care, especially in remote areas. The market also has growth potential through increased focus on lifestyle modifications and preventive care, which could complement traditional treatment options. Strategic partnerships and collaborations between pharmaceutical companies, research institutions, and healthcare providers are crucial for capitalizing on these opportunities and maintaining a competitive edge.

Key Questions Answered in the Report:

• What are the primary factors driving the growth of the Inflammatory Bowel Disease Market globally?
• Which treatment options are leading the adoption in various patient settings?
• How are technological advancements influencing the competitive landscape of the IBD Market?
• Who are the key players in the IBD Market, and what strategies are they employing to stay competitive?
• What are the emerging trends and future prospects in the global Inflammatory Bowel Disease Market?

Competitive Intelligence and Business Strategy:

Leading companies in the global Inflammatory Bowel Disease Market, such as AbbVie Inc., Johnson & Johnson, and Pfizer Inc., focus on innovation, product differentiation, and strategic collaborations to maintain a competitive advantage. These companies invest heavily in R&D to develop advanced therapies for IBD, including biologics and biosimilars, and explore new treatment modalities like gene therapy. Collaborations with research institutions and healthcare providers support the development of novel therapies and promote their adoption in clinical practice. A focus on patient education, high-quality products, and comprehensive marketing strategies drives market growth and strengthens brand loyalty in the evolving IBD Market landscape.

Key Companies Profiled:

• AbbVie Inc.
• Janssen Biotech, Inc.
• Pfizer Inc.
• Takeda Pharmaceutical Company Limited
• Ferring Pharmaceuticals
• Amgen Inc.
• Eli Lilly and Company
• Novartis AG
• Bristol-Myers Squibb
• Johnson & Johnson
• Merck & Co., Inc.
• GlaxoSmithKline plc

Inflammatory Bowel Disease Market Industry Segmentation

By Disease Type

• Crohn's Disease
• Ulcerative Colitis

By Drug Class

• Aminosalicylates
• Corticosteroids
• Immunomodulators
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• E-Commerce Platforms
• Others

By Region

• North America
• Europe
• Asia-Pacific
• The Middle East and Africa
• Latin America

ページTOPに戻る

Table of Contents

1. Executive Summary
1.1. Global Inflammatory Bowel Disease Market Snapshot, 2024-2031
1.2. Market Opportunity Assessment, 2024-2031, US$ Bn
1.3. Key Market Trends
1.4. Future Market Projections
1.5. Premium Market Insights
1.6. Industry Developments and Key Market Events
1.7. PMR Analysis and Recommendations
2. Market Overview
2.1. Market Scope and Definition
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Opportunity
2.2.4. Challenges
2.2.5. Key Trends
2.3. Macro-Economic Factors
2.3.1. Global Sectorial Outlook
2.3.2. Global GDP Growth Outlook
2.3.3. Global Healthcare Spending Outlook
2.4. COVID-19 Impact Analysis
2.5. Forecast Factors – Relevance and Impact
3. Value Added Insights
3.1. Technology Assessment
3.2. Regulatory Landscape
3.3. Value Chain Analysis
3.4. Key Deals and Mergers
3.5. PESTLE Analysis
3.6. Porter’s Five Force Analysis
3.7. Regional Prices and Disease Type Preferences
4. Global Inflammatory Bowel Disease Market Outlook: Historical (2019-2023) and Forecast (2024-2031)
4.1. Key Highlights
4.1.1. Market Size (US$ Bn) and Y-o-Y Growth
4.1.2. Absolute $ Opportunity
4.2. Market Size (US$ Bn) Analysis and Forecast
4.2.1. Historical Market Size (US$ Bn) Analysis, 2019-2023
4.2.2. Current Market Size (US$ Bn) Analysis and Forecast, 2023–2031
4.3. Global Inflammatory Bowel Disease Market Outlook: Disease Type
4.3.1. Introduction / Key Findings
4.3.2. Historical Market Size (US$ Bn) Analysis, By Disease Type, 2019-2023
4.3.3. Current Market Size (US$ Bn) Analysis and Forecast, By Disease Type, 2024-2031
4.3.3.1. Crohn's Disease
4.3.3.2. Ulcerative Colitis
4.4. Market Attractiveness Analysis: Disease Type
4.5. Global Inflammatory Bowel Disease Market Outlook: Drug Class
4.5.1. Introduction / Key Findings
4.5.2. Historical Market Size (US$ Bn) Analysis, By Drug Class, 2019-2023
4.5.3. Current Market Size (US$ Bn) Analysis and Forecast, By Drug Class, 2024-2031
4.5.3.1. Aminosalicylates
4.5.3.2. Corticosteroids
4.5.3.3. Immunomodulators
4.5.3.4. Others
4.6. Market Attractiveness Analysis: Drug Class
4.7. Global Inflammatory Bowel Disease Market Outlook: Distribution Channel
4.7.1. Introduction / Key Findings
4.7.2. Historical Market Size (US$ Bn) Analysis, By Drug Class, 2019-2023
4.7.3. Current Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2024-2031
4.7.3.1. Hospital Pharmacies
4.7.3.2. Retail Pharmacies
4.7.3.3. E-Commerce Platforms
4.7.3.4. Others
4.8. Market Attractiveness Analysis: Distribution Channel
5. Global Inflammatory Bowel Disease Market Outlook: Region
5.1. Key Highlights
5.2. Historical Market Size (US$ Bn) Analysis, By Region, 2019-2023
5.3. Current Market Size (US$ Bn) Analysis and Forecast, By Region, 2024-2031
5.3.1. North America
5.3.2. Europe
5.3.3. East Asia
5.3.4. South Asia and Oceania
5.3.5. Latin America
5.3.6. Middle East & Africa
5.4. Market Attractiveness Analysis: Region
6. North America Inflammatory Bowel Disease Market Outlook: Historical (2019-2023) and Forecast (2024-2031)
6.1. Key Highlights
6.2. Pricing Analysis
6.3. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
6.3.1. By Country
6.3.2. By Disease Type
6.3.3. By Drug Class
6.3.4. By Distribution Channel
6.4. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2031
6.4.1. U.S.
6.4.2. Canada
6.5. Current Market Size (US$ Bn) Analysis and Forecast, By Disease Type, 2024-2031
6.5.1. Crohn's Disease
6.5.2. Ulcerative Colitis
6.6. Current Market Size (US$ Bn) Analysis and Forecast, By Drug Class, 2024-2031
6.6.1. Aminosalicylates
6.6.2. Corticosteroids
6.6.3. Immunomodulators
6.6.4. Others
6.7. Current Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2024-2031
6.7.1. Hospital Pharmacies
6.7.2. Retail Pharmacies
6.7.3. E-Commerce Platforms
6.7.4. Others
6.8. Market Attractiveness Analysis
7. Europe Inflammatory Bowel Disease Market Outlook: Historical (2019-2023) and Forecast (2024-2031)
7.1. Key Highlights
7.2. Pricing Analysis
7.3. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
7.3.1. By Country
7.3.2. By Disease Type
7.3.3. By Drug Class
7.3.4. By Distribution Channel
7.4. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2031
7.4.1. Germany
7.4.2. France
7.4.3. U.K.
7.4.4. Italy
7.4.5. Spain
7.4.6. Russia
7.4.7. Turkey
7.4.8. Rest of Europe
7.5. Current Market Size (US$ Bn) Analysis and Forecast, By Disease Type, 2024-2031
7.5.1. Crohn's Disease
7.5.2. Ulcerative Colitis
7.6. Current Market Size (US$ Bn) Analysis and Forecast, By Drug Class, 2024-2031
7.6.1. Aminosalicylates
7.6.2. Corticosteroids
7.6.3. Immunomodulators
7.6.4. Others
7.7. Current Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2024-2031
7.7.1. Hospital Pharmacies
7.7.2. Retail Pharmacies
7.7.3. E-Commerce Platforms
7.7.4. Others
7.8. Market Attractiveness Analysis
8. East Asia Inflammatory Bowel Disease Market Outlook: Historical (2019-2023) and Forecast (2024-2031)
8.1. Key Highlights
8.2. Pricing Analysis
8.3. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
8.3.1. By Country
8.3.2. By Disease Type
8.3.3. By Drug Class
8.3.4. By Distribution Channel
8.4. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2031
8.4.1. China
8.4.2. Japan
8.4.3. South Korea
8.5. Current Market Size (US$ Bn) Analysis and Forecast, By Disease Type, 2024-2031
8.5.1. Crohn's Disease
8.5.2. Ulcerative Colitis
8.6. Current Market Size (US$ Bn) Analysis and Forecast, By Drug Class, 2024-2031
8.6.1. Aminosalicylates
8.6.2. Corticosteroids
8.6.3. Immunomodulators
8.6.4. Others
8.7. Current Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2024-2031
8.7.1. Hospital Pharmacies
8.7.2. Retail Pharmacies
8.7.3. E-Commerce Platforms
8.7.4. Others
8.8. Market Attractiveness Analysis
9. South Asia & Oceania Inflammatory Bowel Disease Market Outlook: Historical (2019-2023) and Forecast (2024-2031)
9.1. Key Highlights
9.2. Pricing Analysis
9.3. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
9.3.1. By Country
9.3.2. By Disease Type
9.3.3. By Drug Class
9.3.4. By Distribution Channel
9.4. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2031
9.4.1. India
9.4.2. Southeast Asia
9.4.3. ANZ
9.4.4. Rest of South Asia & Oceania
9.5. Current Market Size (US$ Bn) Analysis and Forecast, By Disease Type, 2024-2031
9.5.1. Crohn's Disease
9.5.2. Ulcerative Colitis
9.6. Current Market Size (US$ Bn) Analysis and Forecast, By Drug Class, 2024-2031
9.6.1. Aminosalicylates
9.6.2. Corticosteroids
9.6.3. Immunomodulators
9.6.4. Others
9.7. Current Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2024-2031
9.7.1. Hospital Pharmacies
9.7.2. Retail Pharmacies
9.7.3. E-Commerce Platforms
9.7.4. Others
9.8. Market Attractiveness Analysis
10. Latin America Inflammatory Bowel Disease Market Outlook: Historical (2019-2023) and Forecast (2024-2031)
10.1. Key Highlights
10.2. Pricing Analysis
10.3. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
10.3.1. By Country
10.3.2. By Disease Type
10.3.3. By Drug Class
10.3.4. By Distribution Channel
10.4. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2024-2031
10.4.1. Brazil
10.4.2. Mexico
10.4.3. Rest of Latin America
10.5. Current Market Size (US$ Bn) Analysis and Forecast, By Disease Type, 2024-2031
10.5.1. Crohn's Disease
10.5.2. Ulcerative Colitis
10.6. Current Market Size (US$ Bn) Analysis and Forecast, By Drug Class, 2024-2031
10.6.1. Aminosalicylates
10.6.2. Corticosteroids
10.6.3. Immunomodulators
10.6.4. Others
10.7. Current Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2024-2031
10.7.1. Hospital Pharmacies
10.7.2. Retail Pharmacies
10.7.3. E-Commerce Platforms
10.7.4. Others
10.8. Market Attractiveness Analysis
11. Middle East & Africa Inflammatory Bowel Disease Market Outlook: Historical (2019-2023) and Forecast (2024-2031)
11.1. Key Highlights
11.2. Pricing Analysis
11.3. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2023
11.3.1. By Country
11.3.2. By Disease Type
11.3.3. By Drug Class
11.3.4. By Distribution Channel
11.4. Current Market Size (US$ Bn) Analysis and Forecast, By Disease Type, 2024-2031
11.4.1. Crohn's Disease
11.4.2. Ulcerative Colitis
11.5. Current Market Size (US$ Bn) Analysis and Forecast, By Drug Class, 2024-2031
11.5.1. Aminosalicylates
11.5.2. Corticosteroids
11.5.3. Immunomodulators
11.5.4. Others
11.6. Current Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2024-2031
11.6.1. Hospital Pharmacies
11.6.2. Retail Pharmacies
11.6.3. E-Commerce Platforms
11.6.4. Others
11.7. Market Attractiveness Analysis
12. Competition Landscape
12.1. Market Share Analysis, 2023
12.2. Market Structure
12.2.1. Competition Intensity Mapping by Market
12.2.2. Competition Dashboard
12.3. Company Profiles (Details – Overview, Financials, Strategy, Recent Developments)
12.3.1. AbbVie Inc.
12.3.1.1. Overview
12.3.1.2. Segments and Disease Types
12.3.1.3. Key Financials
12.3.1.4. Market Developments
12.3.1.5. Market Strategy
12.3.2. Janssen Biotech, Inc.
12.3.3. Pfizer Inc.
12.3.4. Takeda Pharmaceutical Company Limited
12.3.5. Ferring Pharmaceuticals
12.3.6. Amgen Inc.
12.3.7. Eli Lilly and Company
12.3.8. Novartis AG
12.3.9. Bristol-Myers Squibb
12.3.10. Johnson & Johnson
12.3.11. Merck & Co., Inc.
12.3.12. GlaxoSmithKline plc
13. Appendix
13.1. Research Methodology
13.2. Research Assumptions
13.3. Acronyms and Abbreviations